Dewpoint Therapeutics nets $150m Series C

Dewpoint Therapeutics Inc, a biomolecular condensates company, has closed $150 million in Series C financing.

3 February 2022•1 min read
Feature image
LinkedInXEmail
LinkedInXEmail

Related articles